NYSE: A - Agilent Technologies

Altı ay boyunca karlılık: -17.88%
Temettü getirisi: +0.74%
Sektör: Healthcare

Haberler

Novo Nordisk shares fall on weight-loss drug trial

11 martha 00:15 Novo Nordisk shares fall on weight-loss drug trial

Build-A-Bear Workshop shocks with 'After Dark' collection of adults-only stuffed animals

18 kasım 18:18 Build-A-Bear Workshop shocks with 'After Dark' collection of adults-only stuffed animals

Shipping giant to resume Red Sea voyages with Operation Prosperity Guardian in place

18 kasım 17:36 Shipping giant to resume Red Sea voyages with Operation Prosperity Guardian in place

Nestlé launches food line targeting Ozempic, other weight-loss drug users

18 kasım 17:12 Nestlé launches food line targeting Ozempic, other weight-loss drug users

Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug

18 kasım 17:05 Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug

Build-A-Bear and Warren Buffett's 'Squishmallows' maker square off in court

18 kasım 16:56 Build-A-Bear and Warren Buffett's 'Squishmallows' maker square off in court

25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says

18 kasım 16:52 25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says

Maersk pauses Red Sea voyages a day after Houthis attack ship

18 kasım 16:29 Maersk pauses Red Sea voyages a day after Houthis attack ship

Ozempic, Wegovy and other weight loss drugs present holiday challenges

18 kasım 16:29 Ozempic, Wegovy and other weight loss drugs present holiday challenges

Janet Yellen walks back Biden's comments US taxpayers on hook for Baltimore bridge collapse

18 kasım 16:26 Janet Yellen walks back Biden's comments US taxpayers on hook for Baltimore bridge collapse

Stoklamak

Aletler

Toplum

Kişiler

2025 © Investing Port
Kişiler | Reklam
Porti.ru malzemelerinin kullanımına yalnızca kaynağa aktif bir indekslenmiş bağlantı olması durumunda izin verilir.